The study on the pathogenesis of spleen-kidney deficiency type myasthenia gravis and the interference effect of Jianji Ning Granule on the patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13004125

Enrollment

Unknown

Registered

2013-06-08

Start date

2010-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia gravis

Interventions

trial:Jianji Ning Granule combined with olfactory pyridostigmine tablets

Control:olfactory pyridostigmine tablets

Eligibility

Sex/Gender

All

Age

14 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) in line with diagnosis of MG based on the Western medicine diagnostic criteria for autoimmune myasthenia gravis9, including symptoms of fluctuating muscle weakness supported by an electromyographic pattern of neuromuscular transmission dysfunction by repetitive stimulation, belonging to the modified Osseman I, IIA, IIB type; (2) patients with Chinese medical diagnosis of flaccidity fitting to the differentiation standard of spleen-kidney deficiency type syndrome 10, Where have the one of the main symptoms and secondary symptoms of more than one, or both, see tongue, pulse can be included; (3) patients were between 14 and 75 years old patients were voluntary; (4) the subjects were informed voluntary and written informed consent to participate the study.

Exclusion criteria

Exclusion criteria: 1. Osseman III, IV, V; 2. Familial MG, congenital myasthenic syndrome and drug (D-penicillamine, interferon induced by MG, etc.); 3. patients who were nursing or pregnant; 4. patients who had comorbid diseases such as cerebrovascular diseases, renal insufficiency, hematopoietic system diseases, and psychiatric diseases; 5. allergies (allergic to more than 2 kinds of food or medicine); 6. The last 1 months participated in other clinical trials of drugs; 7. Once plasma exchange or intravenous gamma globulin in treatment patients in the past three months.

Design outcomes

Primary

Measure	Time frame
MGFA;Chinese Quality of Life Scale;The incidence of recurrent disease;Peripheral serum miRNA microarray detection;	—

Secondary

Measure	Time frame
Improvement rate of Autoimmune myasthenia gravis;Serum acetylcholine receptor antibody detection;Electromyograph;	—

Countries

China

Contacts

Public ContactPing Liu

Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine

641063632@QQ.COM+86 13681717058

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026